A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of NPT189 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs NPT-189 (Primary)
- Indications Amyloidosis
- Focus Adverse reactions
- Sponsors Proclara Biosciences
- 14 Aug 2019 Status changed from recruiting to discontinued.
- 15 Mar 2019 Status changed from planning to recruiting.
- 04 Apr 2018 New trial record